Literature DB >> 30765904

Nitrofurantoin and fosfomycin for resistant urinary tract infections: old drugs for emerging problems.

Bradley J Gardiner1,2,3, Andrew J Stewardson1,2,3, Iain J Abbott1,2,3, Anton Y Peleg1,2,3.   

Abstract

Entities:  

Keywords:  antibiotic resistance; fosfomycin; nitrofurantoin; urinary tract infection

Year:  2019        PMID： 30765904      PMCID： PMC6370609          DOI： 10.18773/austprescr.2019.002

Source DB:  PubMed          Journal:  Aust Prescr        ISSN： 0312-8008


× No keyword cloud information.
  62 in total

1.  The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America.

Authors:  Brad Spellberg; Robert Guidos; David Gilbert; John Bradley; Helen W Boucher; W Michael Scheld; John G Bartlett; John Edwards
Journal:  Clin Infect Dis       Date:  2008-01-15       Impact factor: 9.079

2.  Nitrofurantoin retains antimicrobial activity against multidrug-resistant urinary Escherichia coli from US outpatients.

Authors:  G V Sanchez; A M G Baird; J A Karlowsky; R N Master; J M Bordon
Journal:  J Antimicrob Chemother       Date:  2014-07-25       Impact factor: 5.790

3.  Phosphonomycin, a new antibiotic produced by strains of streptomyces.

Authors:  D Hendlin; E O Stapley; M Jackson; H Wallick; A K Miller; F J Wolf; T W Miller; L Chaiet; F M Kahan; E L Foltz; H B Woodruff; J M Mata; S Hernandez; S Mochales
Journal:  Science       Date:  1969-10-03       Impact factor: 47.728

4.  Comparison of fosfomycin to ertapenem for outpatient or step-down therapy of extended-spectrum β-lactamase urinary tract infections.

Authors:  Michael P Veve; Jamie L Wagner; Rachel M Kenney; Jenny L Grunwald; Susan L Davis
Journal:  Int J Antimicrob Agents       Date:  2016-05-12       Impact factor: 5.283

Review 5.  Fosfomycin versus other antibiotics for the treatment of cystitis: a meta-analysis of randomized controlled trials.

Authors:  Matthew E Falagas; Evridiki K Vouloumanou; Antonios G Togias; Maria Karadima; Anastasios M Kapaskelis; Petros I Rafailidis; Stavros Athanasiou
Journal:  J Antimicrob Chemother       Date:  2010-06-29       Impact factor: 5.790

Review 6.  Ceftolozane/tazobactam (CXA 201) for the treatment of intra-abdominal infections.

Authors:  Emilio Maseda; Lorenzo Aguilar; Maria-Jose Gimenez; Fernando Gilsanz
Journal:  Expert Rev Anti Infect Ther       Date:  2014-08-20       Impact factor: 5.091

7.  Collateral damage from oral ciprofloxacin versus nitrofurantoin in outpatients with urinary tract infections: a culture-free analysis of gut microbiota.

Authors:  A J Stewardson; N Gaïa; P François; S Malhotra-Kumar; C Delémont; B Martinez de Tejada; J Schrenzel; S Harbarth; V Lazarevic
Journal:  Clin Microbiol Infect       Date:  2014-11-25       Impact factor: 8.067

8.  Fosfomycin trometamol in a single dose versus seven days nitrofurantoin in the treatment of acute uncomplicated urinary tract infections in women.

Authors:  E Van Pienbroek; J Hermans; A A Kaptein; J D Mulder
Journal:  Pharm World Sci       Date:  1993-12-17

9.  Dissemination of plasmid-mediated fosfomycin resistance fosA3 among multidrug-resistant Escherichia coli from livestock and other animals.

Authors:  P L Ho; J Chan; W U Lo; P Y Law; Z Li; E L Lai; K H Chow
Journal:  J Appl Microbiol       Date:  2012-12-27       Impact factor: 3.772

Review 10.  Nitrofurantoin--current concepts.

Authors:  B A Cunha
Journal:  Urology       Date:  1988-07       Impact factor: 2.649
View more
  19 in total

1.  Emerging Antibiotic Resistance to Bacterial Isolates from Human Urinary Tract Infections in Grenada.

Authors:  Deepak Sharma; Sara E Preston; Robert Hage
Journal:  Cureus       Date:  2019-09-25

2.  Effect of kitasamycin and nitrofurantoin at subinhibitory concentrations on quorum sensing regulated traits of Chromobacterium violaceum.

Authors:  Yasser Musa Ibrahim; Ahmed Megahed Abouwarda; Farghaly Abdelhamid Omar
Journal:  Antonie Van Leeuwenhoek       Date:  2020-09-05       Impact factor: 2.271

3.  Efficacy of Single Dose of Fosfomycin Versus a Five-Day Course of Ciprofloxacin in Patients With Uncomplicated Urinary Tract Infection.

Authors:  Muhammad Mujeeb Hassan; Moeena Malik; Rabia Saleem; Amna Saleem; Khurram Zohaib; Adnan Younas Malik; Maham Javaid
Journal:  Cureus       Date:  2022-05-09

4.  Fosfomycin and breastfeeding.

Authors: 
Journal:  Aust Prescr       Date:  2020-08-01

5.  Multiple-Dose Oral Fosfomycin for Treatment of Complicated Urinary Tract Infections in the Outpatient Setting.

Authors:  Catherine G Derington; Nancy Benavides; Thomas Delate; Douglas N Fish
Journal:  Open Forum Infect Dis       Date:  2020-01-29       Impact factor: 3.835

6.  Treatment of Cystitis by Hungarian General Practitioners: A Prospective Observational Study.

Authors:  Ria Benko; Maria Matuz; Zoltan Juhasz; Julia Bognar; Reka Bordas; Gyongyver Soos; Edit Hajdu; Zoltan Peto
Journal:  Front Pharmacol       Date:  2019-12-19       Impact factor: 5.810

7.  Broiler Farms and Carcasses Are an Important Reservoir of Multi-Drug Resistant Escherichia coli in Ecuador.

Authors:  David Ortega-Paredes; Sofía de Janon; Fernando Villavicencio; Katherine Jaramillo Ruales; Kenny De La Torre; José E Villacís; Jaap A Wagenaar; Jorge Matheu; Camila Bravo-Vallejo; Esteban Fernández-Moreira; Christian Vinueza-Burgos
Journal:  Front Vet Sci       Date:  2020-11-25

8.  Heterogeneity of Antibiotics Multidrug-Resistance Profile of Uropathogens in Romanian Population.

Authors:  Răzvan-Cosmin Petca; Silvius Negoiță; Cristian Mareș; Aida Petca; Răzvan-Ionuț Popescu; Călin Bogdan Chibelean
Journal:  Antibiotics (Basel)       Date:  2021-05-02

9.  Reciprocal Cooperation of Type A Procyanidin and Nitrofurantoin Against Multi-Drug Resistant (MDR) UPEC: A pH-Dependent Study.

Authors:  Sahana Vasudevan; Gopalakrishnan Thamil Selvan; Sunil Bhaskaran; Natarajan Hari; Adline Princy Solomon
Journal:  Front Cell Infect Microbiol       Date:  2020-08-11       Impact factor: 5.293

10.  Assessment of Nitrofurantoin as an Experimental Intracanal Medicament in Endodontics.

Authors:  Mewan Salahalddin A Alrahman; Bestoon Muhammed Faraj; Kawa F Dizaye
Journal:  Biomed Res Int       Date:  2020-02-18       Impact factor: 3.411
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.